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ABSTRACT
Introduction Up to 40% of orthopaedic injuries in children
require a closed reduction, almost always necessitating
procedural sedation. Intravenous ketamine is the most
commonly used sedative agent. However, intravenous
insertion is painful and can be technically difficult in
children. We hypothesise that a combination of intranasal
dexmedetomidine plus intranasal ketamine (Ketodex)
will be non-inferior to intravenous ketamine for effective
sedation in children undergoing a closed reduction.
Methods and analysis This is a six-centre, four-arm,
adaptive, randomised, blinded, controlled, non-inferiority
trial. We will include children 4–17 years with a simple
upper limb fracture or dislocation that requires sedation
for a closed reduction. Participants will be randomised
to receive either intranasal Ketodex (one of three
dexmedetomidine and ketamine combinations) or
intravenous ketamine. The primary outcome is adequate
sedation as measured using the Paediatric Sedation State
Scale. Secondary outcomes include length of stay, time
to wakening and adverse effects. The results of both per
protocol and intention-to-treat analyses will be reported
for the primary outcome. All inferential analyses will be
undertaken using a response-adaptive Bayesian design.
Logistic regression will be used to model the dose–
response relationship for the combinations of intranasal
Ketodex. Using the Average Length Criterion for Bayesian
sample size estimation, a survey-informed non-inferiority
margin of 17.8% and priors from historical data, a sample
size of 410 participants will be required. Simulations
estimate a type II error rate of 0.08 and a type I error rate
of 0.047.
Ethics and dissemination Ethics approval was obtained
from Clinical Trials Ontario for London Health Sciences
Centre and McMaster Research Ethics Board. Other
sites have yet to receive approval from their institutions.
Informed consent will be obtained from guardians of all
participants in addition to assent from participants. Study
data will be submitted for publication regardless of results.

Strengths and limitations of this study
►► This study employs a response adaptive trial design

to overcome gaps in our current understanding of
the most effective dosing combination of intranasal
Ketodex.
►► To optimise trial efficiency, frequent assessment of
the data will be used to adapt the trial to increase
the number of participants receiving the more effective combination of Ketodex.
►► This study involved a patient engagement strategy
whereby patient partners informed the eligibility criteria and outcomes, and reviewed letters of information, consent and assent.
►► We expect that current translation to practice may
be limited by the high volume of intranasal drug
required for older children unless a higher concentration of ketamine (100 mg/kg) becomes widely
available.
►► Research nurses may become aware of group assignment and blinding will only be possible for outcome assessors.

Trial registration number NCT0419525.

INTRODUCTION
Orthopaedic injuries comprise more than
10% of emergency department (ED) visits
in children,1 2 and 25%–50% of children will
sustain a fracture before the age of 16 years.3
Between 20% and 40% of extremity fractures
in children require a closed reduction,4 5
often necessitating procedural sedation. The
demand for procedural sedation in children
outside the operating room is increasing
at a rate of 10% annually.6 7 As such, the
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METHODS AND ANALYSIS
Design
This is a six-
centre, four-
arm, randomised, blinded,
double-dummy, controlled, parallel group, adaptive dose-
finding, non-inferiority, phase II/III trial. The trial will
determine whether intranasal Ketodex is non-inferior to
intravenous ketamine for children undergoing procedural sedation and analgesia determine the optimal
dosing combination for intranasal Ketodex. The study
protocol is reported using the SPIRIT-
PRO reporting
guidelines.22
2

Study setting
This study will be conducted in six paediatric EDs across
Canada: (1) Children’s Hospital at London Health
Sciences Centre (London, Ontario) (coordinating site);
(2) Stollery Children’s Hospital (Edmonton, Alberta); (3)
BC Children’s Hospital (Vancouver, British Columbia);
(4) Winnipeg Children’s Hospital (Winnipeg, Manitoba); (5) CHEO (Ottawa, Ontario); and (6) McMaster
Children’s Hospital (Hamilton, Ontario). The annual ED
census for recruiting centres ranges from 30 000 to 70 000
patient visits.
Eligibility
Children will be eligible if they meet all of the following
criteria: (1) provision of signed and dated informed
consent form; (2) stated willingness to comply with all
study procedures and availability for the duration of the
study; (3) deemed by treating physician to require procedural sedation; (4) aged 4–17 years; (5) weighing up to
and including 60 kg; (6) one of the following injuries:
forearm fracture, metacarpal or phalangeal fracture, or
dislocation of a shoulder or elbow; (7) closed reduction
expected to take no more than 5 min to reduce (as determined by the procedure physician and not including cast
or splint application); and (8) both nares are fully patent.
Exclusion criteria are listed in table 1.
Interventions and permissible cointerventions
Eligible participants will be randomised to intranasal
Ketodex or intravenous ketamine with a 3:2 allocation
ratio. Participants receiving intranasal Ketodex will be
further adaptively randomised to three alternative combinations where the randomisation ratio is proportional to
the posterior probability that a combination is optimal in
terms of providing adequate sedation. A double-dummy
approach will be used to overcome the possibility of
unmasking due to perceptible differences in interventional routes. This involves each participant receiving
both an intranasal and intravenous intervention, only
one of which is the real drug. Both intranasal and intravenous interventions will be administered through any of
the following:
1. Dexmedetomidine (Pfizer, Kirkland, Quebec), single
dose, 4 mcg/kg (0.04 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL), then ketamine
(Sandoz, Mississauga, Ontario), single dose, 2 mg/
kg (0.04 mL/kg) of 50 mg/mL solution, maximum of
200 mg (4 mL) (D4K2), both delivered intranasally using a mucosal atomiser device (MAD) and divided to
both nares and 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL.
2. Dexmedetomidine (Pfizer), single dose, 3 mcg/kg
(0.03 mL/kg) of 100 mcg/mL solution, maximum of
200 mcg (2 mL), then ketamine (Sandoz), single dose,
3 mg/kg (0.06 mL/kg) of 50 mg/mL solution, maximum of 300 mg (6 mL) (D3K3), both delivered intranasally using MAD and divided to both nares and 0.9%
Poonai N, et al. BMJ Open 2020;10:e041319. doi:10.1136/bmjopen-2020-041319
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placement of an intravenous catheter for procedural
sedation is extremely common. However, children rate
intravenous insertion as one of the most painful hospital
experiences, second only to the painful condition itself.8
intravenous insertion can be more technically difficult in
children because of smaller veins9 and lack of cooperation,8 9 often leading to multiple intravenous attempts.
Intranasal medications may obviate the need for
distressing intravenous placement and offer a technically
easier and pain-free approach to procedural sedation.10
This may have widespread applicability in patients with
difficult intravenous access, resource-
limited settings,
needle phobia or when experience placing an intravenous
is limited. Ketamine is the most commonly used sedative
agent for fracture reduction in children11 and intranasal
ketamine has been found to be effective for fracture
pain,10 some procedural pain,12 anaesthetic preinduction13 and diagnostic imaging.14 However, neither agent
has been studied for procedural sedation to reduce fractures or dislocations. Dexmedetomidine is a central alpha
2-adrenergic receptor agonist with analgesic and anxiolytic properties and is effective for procedural anxiety in
children in its intravenous form.2 15 16 A recent systematic
review of intranasal dexmedetomidine in children undergoing painful procedures (dental procedures, venipuncture and laceration repair) found doses ranging from 1
to 4 mcg/kg were well tolerated and superior to conventional sedatives (oral chloral hydrate and oral and intranasal midazolam) in providing adequate sedation.17
However, procedural sedation for orthopaedic reduction may require agents with greater sedative and analgesic potency. Preliminary evidence suggests that a
combination of dexmedetomidine and ketamine may
be superior than either agent alone.18 19 A combination
of intranasal ketamine and intranasal dexmedetomidine
(‘Ketodex’) theoretically combines the analgesic efficacy
of ketamine20 with the sedative efficacy of dexmedetomidine.21 However, there remains uncertainty regarding the
ideal combination of these two agents. In order to provide
robust evidence supporting an alternate approach that
precludes the need for an intravenous in children undergoing sedation, a response-adaptive Bayesian design will
be used to determine the most effective combination of
Ketodex and to test our hypothesis of whether this combination is non-inferior to intravenous ketamine.

Open access

Data category

Information

Primary registry and trial identifying number
Date of registration in primary registry

clinicaltrials.gov
15 August 2019

Secondary identifying numbers

Clinical Trials Ontario # 1987

Sources of monetary or material support

Canadian Institutes of Health Research SPOR Innovative Clinical Trials
Grant (MYG-151207)
Physicians Services Incorporated Foundation
Academic Medical Organisation of Southwestern Ontario
Ontario Ministry of Economic Development, Job Creation and Trade Early
Researcher Award

Primary sponsor

Lawson Health Sciences Research Institute

Secondary sponsor

–

Contact for public queries

Dr Naveen Poonai, naveen.poonai@lhsc.on.ca

Contact for scientific queries

Dr Naveen Poonai, naveen.poonai@lhsc.on.ca

Public title

The Ketodex study

Scientific title

Adaptive randomised controlled non-inferiority multicentre trial (the
Ketodex trial) on intranasal dexmedetomidine plus ketamine for
procedural sedation in children study protocol

Countries of recruitment

Canada

Health conditions or problems studied
Interventions

Fracture, dislocation
1. Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 4 mcg/kg
(0.04 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL),
then ketamine (Sandoz, Mississauga, Ontario), single dose, 2 mg/
kg (0.04 mL/kg) of 50 mg/mL solution, maximum of 200 mg (4 mL)
(D4K2), both delivered intranasally using a MAD and divided to both
nares, and 0.9% normal saline 0.03 mL/kg delivered intravenously to a
maximum of 2 mL or
2. Dexmedetomidine (Pfizer), single dose, 3 mcg/kg (0.03 mL/kg) of
100 mcg/mL solution, maximum of 200 mcg (2 mL) then ketamine
(Sandoz), single dose, 3 mg/kg (0.06 mL/kg) of 50 mg/mL solution,
maximum of 300 mg (6 mL) (D3K3), both delivered intranasally using
a MAD and divided to both nares and 0.9% normal saline 0.03 mL/kg
delivered intravenously to a maximum of 2 mL or
3. Dexmedetomidine (Pfizer), single dose, 2 mcg/kg (0.02 mL/kg) of
100 mcg/mL solution, maximum of 200 mcg (2 mL) then ketamine
(Sandoz), single dose, 4 mg/kg (0.08 mL/kg) of 50 mg/mL solution,
maximum of 400 mg (8 mL) (D2K4), both delivered intranasally using
MAD and divided to both nares and 0.9% normal saline 0.03 mL/kg
delivered intravenously to a maximum of 2 mL or
4. Ketamine, single dose, 1.5 mg/kg (0.03 mL/kg) of 50 mg/mL solution
delivered intravenously, to a maximum of 100 mg (2 mL) and two
aliquots of 0.9% normal saline in three possible combinations: (1)
0.04 mL/kg (max 2 mL) then 0.04 mL/kg (max 4 mL) (placebo D4K2), (2)
0.03 mL/kg (max 2 mL) then 0.06 mL/kg (max 6 mL) (placebo D3K3), (3)
0.02 mL/kg (max 2 mL) then 0.08 mL/kg (max 8 mL) (placebo D2K4),
delivered intranasally using MAD and divided to both nares.
Continued
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Table 1 Trial registration dataset

Open access

Data category

Information

Key inclusion and exclusion criteria

General criteria
1. Provision of signed and dated informed consent form.
2. Stated willingness to comply with all study procedures and availability
for the duration of the study.
3. Deemed by treating physician to require procedural sedation.
Inclusion criteria
1. Children presenting to the paediatric emergency departments of
participating sites age 4–17 years.
2. Weighing up to and including 60 kg.
3. One of the following injuries:
4. Forearm fracture.
5. Metacarpal or phalangeal fracture.
6. Dislocation of a shoulder or elbow.
7. Closed reduction expected to take no more than 5 min of manipulation
to reduce (as determined by the procedure physician and not including
cast or splint application).
Both nares are fully patent.

Exclusion criteria

Previous hypersensitivity reaction to ketamine or dexmedetomidine
including rash, difficulty breathing, hypotension, apnea or
laryngospasm.
Suspected globe rupture.
Concomitant traumatic brain injury with known intracranial
haemorrhage.
Uncontrolled hypertension.
Nasal bone deformity or septal deviation.
Poor English or French fluency in the absence of native language
interpreter.
American Society of Anesthesiologists Class III or greater.
Previous diagnosis of schizophrenia or active psychosis as per the
treating physician.
Neurocognitive impairment that precludes the ability to self-report pain
and satisfaction.
More than one fracture or dislocation requiring reduction.
Haemodynamic compromise as per the treating physician.
Glasgow coma score <15.
Previous sedation with ketamine within 24 hours.
Fracture is comminuted or associated with a dislocation.
Participant has undergone a haematoma block within 24 hours.
Previous enrolment in the trial.
Suspected pregnancy.
Congenital heart disease or known cardiac dysrhythmia.
Known or suspected hepatic impairment.
Known renal insufficiency.
Uncorrected mineralocorticoid deficiency.
Obstructive sleep apnoea.
Study type

Randomised, blinded, double-dummy, controlled, parallel group, adaptive
dose-finding, non-inferiority, phase II/III trial

Date of first enrolment

11 March 2020

Sample size
Recruitment status

410
Actively recruiting
Continued
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Table 1 Continued

Open access

Data category

Information

Primary outcomes

Adequate sedation for the duration of the procedure. For closed
reduction, this is defined as the interval of time from the first application
of traction or manipulation of the injured limb for the purpose of
anatomical realignment to the last application of a realigning force.
Adequate is defined as fulfilment of all three of the following criteria:
1. A PSSS score of 2 or 3 for the duration of the procedure.
2. No additional medication is given during the procedure for the
purpose of sedation.
3. The patient did not actively resist, cry or require physical restraint for
completion of the closed reduction.

Key secondary outcomes

Length of stay (min): defined as the time recorded in the medical record
between triage and discharge. This is an important consideration to the
uptake of intranasal Ketodex in practice.
Time to wakening: defined as the duration of time between the first pair
or intranasal sprays to the first PSSS score of >3, postclosed reduction.
AEs: AEs are based on Health Canada reporting standards. They include
nasal irritation, which will be assessed using the Faces Pain Scale
Revised immediately prior to discharge and maladaptive behaviours
24–48 hours postrecovery, which will be assessed using the PHBQ.
The FPS-R will be administered using an iPad and the PHBQ will be
administered through an automated email survey from REDCap or by
telephone.

Other endpoints

1. Length of stay due to PSA is the time interval between the first pair of
intranasal sprays to discharge.
2. Duration of procedure is the time interval between the first pair
of intranasal sprays/intravenous dose to the end of cast or splint
application.
3. Length of stay is the time interval between triage assessment and
discharge.
4. Caregiver, participant, bedside nurse or respiratory therapist, and
physician satisfaction with sedation will be recorded at the index visit
using a Visual Analogue Scale. For the caregiver and participant, the
following questions will be posed immediately prior to discharge: how
satisfied were you with your child’s sedation? (caregiver); how happy
were you with your sleep? (participant). For the healthcare providers,
the following question will be posed immediately following cast/splint
application: how satisfied were you with the level of sedation in your
patient?
5. Nasal irritation: discomfort associated with nasal sprays (if recalled),
assessed by the research nurse using the FPS-R at discharge.
6. Volume of intranasal intervention received compared with volume of
intranasal intervention calculated to be received will be recorded at the
index visit.
7. Adjunctive intravenous therapy and medications (eg, analgesics,
antibiotics, antiemetics and fluids) will be recorded at the index visit.
8. Presedation pain will be recorded by the research nurse from the
participant using the FPS-R immediately prior to the first pair of
intranasal sprays.
9. Patient preference for the method of sedation will be recorded at the
index visit by asking the participant: if you were to be put to sleep
again for an injury, what would you prefer, an intravenous needle or
nasal sprays (choose one)?

Ethics review

Clinical Trials Ontario # 1987

Completion date

–

Summary results
IPD sharing statement

–
Deidentified data can be shared, on a case-by-case basis, on discussion
with the principal investigator.
Continued
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Table 1 Continued

Open access

Data category

Information

AE, adverse event; FPS-R, faces pain scale—revised; MAD, mucosal atomiser device; PHBQ, posthospital behaviour questionnaire; PSA,
Procedural sedation and analgesia; PSSS, paediatric sedation state scale; REDCap, Research Electronic Data Capture .

normal saline 0.03 mL/kg delivered intravenously to a
maximum of 2 mL.
3. Dexmedetomidine (Pfizer), single dose, 2 mcg/kg
(0.02 mL/kg) of 100 mcg/mL solution, maximum of
200 mcg (2 mL), then ketamine (Sandoz), single dose,
4 mg/kg (0.08 mL/kg) of 50 mg/mL solution, maximum of 400 mg (8 mL) (D2K4), both delivered intranasally using MAD and divided to both nares and 0.9%
normal saline 0.03 mL/kg delivered intravenously to a
maximum of 2 mL.
4. Ketamine, single dose, 1.5 mg/kg (0.03 mL/kg) of
50 mg/mL solution delivered intravenously, to a maximum of 100 mg (2 mL) and two aliquots of 0.9% normal saline in three possible combinations: (1) 0.04 mL/
kg (max 2 mL) then 0.04 mL/kg (max 4 mL) (placebo
D4K2), (2) 0.03 mL/kg (max 2 mL) then 0.06 mL/
kg (max 6 mL) (placebo D3K3), and (3) 0.02 mL/kg
(max 2 mL) then 0.08 mL/kg (max 8 mL) (placebo
D2K4), delivered intranasally using MAD and divided
to both nares.
Participants will be positioned in a recumbent supine
position at 45°. Each pair of sprays will be separated by at
least 60 s. The physician or their designate must administer the intravenous intervention 30–40 min after the
intranasal dexmedetomidine/saline sprays. The research
or bedside nurses will administer intranasal interventions, and the physician or their designate will administer
intravenous interventions (figure 1).
All participants will receive continuous cardiorespiratory monitoring, consisting of five-lead continuous ECG,
oxygen saturation and blood pressure, with consideration
of capnography. This will commence immediately prior
to administration of the intervention and will continue
until the participant is awake.
The treating physician will not be permitted to
prescribe any sedative, anxiolytic or analgesic cointervention within 15 min of the study intervention. Analgesics
for pain and antiemetics may be given at any time at the
discretion of the clinician or nurse outside the procedural
sedation period. Anxiolytics for emergence agitation or
anxiety may be given following the closed reduction. Any
prescribed home or over-the-counter medications may be
given at any time during the index visit with the exception
of sedatives.

Figure 1

6

Rescue sedation may be provided if, after 1 min
following the intravenous intervention, either of the
following conditions are met: (1) the participant is still
responding to surroundings or (2) procedure has begun
and the participant’s vocalisations are consistent with
pain, or the participant is withdrawing or localising to
pain.
Randomisation and allocation concealment
Randomisation will be performed in two stages as follows:
1. First, the pharmacy at each site will randomise participants in a 3:2 allocation ratio to intranasal Ketodex or
intravenous ketamine and will adapt a previously published design.23 This stage will be stratified by site and
will be randomised in a block size known only to the
statistical team.
2. Second, participants in the Ketodex group will be
adaptively randomised using REDCap to three possible combinations of intranasal ketamine and intranasal dexmedetomidine in a 1:1:1 ratio for the first 150
participants: 2 mg/kg intranasal ketamine+4 μg/kg intranasal dexmedetomidine or 3 mg/kg intranasal ketamine+3 μg/kg intranasal dexmedetomidine or 4 mg/
kg intranasal ketamine+2 μg/kg intranasal dexmedetomidine). After the first 150 participants, the randomisation ratio will be adapted after every 50 recruited
participants. The allocation ratio will be set equal to the
posterior probability that a given dose is the most effective given all the available data at each interim analysis
(200, 250, 300 and 350 participants). The number of
participants randomised to each combination will be
adapted throughout the trial to increase the number
of participants receiving the more effective intranasal
Ketodex combination. Intranasal Ketodex combinations will be dropped if the probability that this dose
is optimal falls below 0.05. Two combinations will be
dropped if there is a greater than 95% chance that a
single combination is optimal. If all dose combinations
have a probability of being the most effective of less
than 50% after 250 participants have been enrolled in
the trial, the safety profile will be evaluated to determine the most promising combination in conjunction
with the data safety monitoring board (DSMB). This

Intervention administration.
Poonai N, et al. BMJ Open 2020;10:e041319. doi:10.1136/bmjopen-2020-041319
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Open access

Blinding
Blinded parties include the participant, caregiver,
research nurse videotaping the procedure and outcome
assessor. Participants should not be aware of group assignment because 0.9% normal saline, dexmedetomidine and
ketamine solutions are odourless, colourless and tasteless. Kits containing the interventions will be identically
appearing, differing only by a study number. However,
differences in onset of sedation between intravenous
ketamine and intranasal Ketodex risk unblinding the
sedating physician, research nurse and outcome assessor.
To minimise this risk, the intravenous intervention will be
given 30–40 min following the intranasal dexmedetomidine/saline sprays due to intranasal dexmedetomidine’s
longer onset of action (20–30 min)21 versus intravenous
ketamine (1 min).24 To increase the probability that both
components of intranasal Ketodex are clinically effective
at the same time, a green-labelled vial containing intranasal dexmedetomidine or saline will be administered
first, followed by a white-labelled vial containing either
intranasal ketamine or saline.
The research nurse will record the video of the participant’s entire body (including the face) starting immediately prior to the closed reduction and continuing until
the reduction is complete. Two trained and independent
outcome assessors remote from the clinical encounter
and unaware of the study objectives will score sedation
using the Paediatric Sedation State Scale (PSSS) (and
determine the primary outcome) every 30 s for the entire
length of the video. The second outcome assessor will
score a randomly selected 25% sample of the participant
videos to generate an inter-rater agreement. Flags will
alert the outcome assessor when the closed reduction
procedure is started and completed.
Poonai N, et al. BMJ Open 2020;10:e041319. doi:10.1136/bmjopen-2020-041319

Unblinding procedures
The DSMB may request unblinding directly from the
DCC statistician. Urgent unblinding may be done if the
participant suffers an adverse event (AE), the management of which is predicated on knowing the group assignment. The research nurse will log into a secure web-based
unblinding system with REDCap, where the study medication will be revealed only to the treating physician.
Thus, caregivers, children and research staff, including
outcome assessors, will remain blinded.
Recruitment
Potential participants will be screened and enrolled
consecutively during the hours of research nurse availability (≤8 hours/day, 7 days/week). Families will provide
verbal consent for eligibility screening by the research
nurse. For patients who pass initial screening, the
research nurse will confirm eligibility with the ED physician or their designate (any clinician who has the capacity
to assess, manage and discharge a patient). If eligibility
is confirmed, the research nurse will explain the study
protocol and seek informed consent (and assent when
appropriate) (see online supplemental files 1 and 2).
Mature minor consent forms will be available for both
accompanied and unaccompanied minors. Research
nurse will record basic demographic features and eligibility criteria of all children with an orthopaedic injury
requiring procedural sedation during their availability,
whether randomised or not, to assess for enrolment bias.
Data collection
All outcomes and endpoints apart from the determination of adequate sedation (the primary outcome) will
be collected by the research nurse and recorded using
REDCap and a Wi-Fi-enabled iPad device.
The research nurse will record a video of the participant’s closed reduction using a Canon VIXIA HF R700
camcorder mounted on a tripod. Once data collection is
completed, the video file will be uploaded onto a shared
drive, which will be accessed only by the two outcome
assessors. Training for the outcome assessors will consist
of a 1-hour PowerPoint presentation that outlined PSSS
scoring and hands-on training using videos of 25 children
who underwent procedural sedation.
Following the application of a cast or splint, the research
nurse will obtain satisfaction scores from the sedating
provider, bedside nurse and participant. Research nurses
will be trained on the recognition and definition of all
expected and unexpected AEs.24–26 The research nurse
will record AEs from the medical record and queries from
healthcare staff during sedation and recovery. Uncertainty
will be clarified with the sedating physician. All AEs will
be recorded except for expected physiological effects of
ketamine such as elevated blood pressure and heart rate,
increased oral secretions, nystagmus, enhanced skeletal
muscle tone, flushing and confusion on wakening.27 28
When the participant is awake, the research nurse will
ask participants to rate their nasal irritation related to
7
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will be used as the single intranasal Ketodex comparator for the remainder of the trial.
NB. Participants in the intravenous ketamine group
will also undergo the second stage of randomisation but
will receive saline in the identical volumes to the active
drug, that is, two aliquots of 0.9% normal saline in three
possible combinations: (1) 0.04 mL/kg (max 2 mL) then
0.04 mL/kg (max 4 mL), (2) 0.03 mL/kg (max 2 mL)
then 0.06 mL/kg (max 6 mL) and (3) 0.02 mL/kg (max
2 mL) then 0.08 mL/kg (max 8 mL).
The allocation tables will be generated by the data
coordinating centre (DCC) statistician at the Women and
Children’s research Institute at the University of Alberta
using R. The allocation tables across the different dose
combinations will be updated at 150, 200, 250, 300 and
350 participants. An independent statistician will validate
the tables and the code that was used to create them. The
tables will then be provided to site pharmacies for creation
of the study kits, ensuring that study staff remain blinded.
Site pharmacies will prepare identically appearing study
kits containing the intravenous and intranasal interventions in accordance with the allocation tables.

Open access

Outcome measures
The primary efficacy outcome is adequate sedation for
the duration of the procedure as we believed this to be
the most salient patient-oriented outcome. Sedation will
be deemed ‘adequate’ if all of the following conditions
are met: (1) a PSSS score of 2 or 3 for the duration of
closed reduction; (2) no additional medication is given
during the procedure for the purpose of sedation; and
(3) the patient did not actively resist, cry or require physical restraint for completion of the procedure. The PSSS
(figure 2) is an instrument developed for assessment of
sedation in children aged 1–7 years undergoing laceration repair using video scoring.30 The PSSS is scored from
0 to 5, with a higher number indicating a lesser degree of
sedation. The PSSS assesses pain as well as oversedation
and undersedation. Adequate sedation is a score of 2 or
330 and represents a level of sedation that correlates with
a lack of pain, distress or oversedation or undersedation;
optimal for procedural sedation as outlined by the Joint
Commission, the American Academy of Paediatrics31 and
the American Society of Anaesthesia.32
Secondary outcomes include the following:
1. Length of stay is the time interval between triage and
discharge.
2. Time to wakening is the time interval between the first
pair or intranasal sprays to the first PSSS score of >3
postclosed reduction as determined by the research
nurse.
3. AEs are based on Health Canada reporting standards
(see online supplemental file 3). They include nasal irritation, which will be assessed using the FPS-R33 immediately prior to discharge and maladaptive behaviours
24–48 hours postrecovery, which will be assessed using
the PHBQ.29 The FPS-R will be administered using an
iPad, and the PHBQ will be administered through an
automated email survey from REDCap or by telephone.
All AEs will be classified according to the Medical
Dictionary for Regulatory Activities (MedDRA).
Other endpoints are listed in table 1.
Sample size
Two surveys were disseminated to over 200 paediatric
and general emergency physicians across Canada. We
presented the case of a 5-year-old girl meeting the study’s
inclusion criteria. We asked respondents to choose single-
dose intravenous or intranasal ketamine for procedural
sedation and to specify the largest percentage of children
who failed intranasal sedation they would be willing to
accept in order to routinely attempt the intranasal route
first. From these surveys, the average non-
inferiority
8

margin η  was 17.8%. To determine a maximum sample
size, we used the Average Length Criterion (ALC) for
Bayesian sample size estimation.34 This method selects
the smallest sample size required to ensure that the 95%
posterior credible interval has an average length of 0.07.
We also considered four alternative randomisation strategies of intravenous ketamine to intranasal Ketodex:
1:4, 3:7, 2:3 and 1:1. The ALC determines the maximum
sample size and the randomisation ratio between intravenous ketamine and intranasal Ketodex. First, we selected
the smallest sample size for which the average length of
the 95% posterior credible interval fell below 0.07. For
this sample size, we then selected the randomisation ratio
that led to the most balanced trial, provided the average
length of the 95% posterior credible interval remained
below 0.07. We used 2000 simulations to estimate the
average posterior credible interval; the posteriors were
approximated using 2000 simulation, for sample sizes
increasing in increments of 10, across all four randomisation regimes. Based on this analysis, the sample size for
the Ketodex trial is 410 patients randomised at a 3:2 ratio
of intranasal Ketodex to intravenous ketamine.
Statistical methods
The results of both per protocol and intention to treat
analyses will be reported for the primary outcome, with
the intention-to-treat analysis being taken as the primary
analysis. Demographic data will be summarised using
frequencies and percentages for categorical variables
and means, medians, SD and IQRs for continuous variables. Length of stay, onset of sedation and duration of
sedation will be analysed using a linear dose–response
model to estimate the mean duration for the optimal
intranasal Ketodex combination. Adverse effects (AEs)
will be analysed using a logistic dose–response model
for intranasal Ketodex and a binomial distribution for
intravenous ketamine. We will use logistic regression
to investigate the interaction between baseline pain,
measured using the FPS-R, considered as a continuous
variable, and treatment effect. All inferential analyses
will be undertaken using a Bayesian framework with
significance declared based on posterior probabilities.
We will use 95% high-density posterior credible interval
estimates to report treatment effect estimates. Due to
the likelihood principal, no adjustments will be made for
multiplicity and type I error will be controlled through
prior specification. Descriptive statistics will be reported
as frequencies and percentages for discrete variables and
means, medians, SD and IQRs for continuous variables.
A statistical analysis plan is being published separately
and includes comprehensive details of prior specification. The primary analysis will determine if the optimal
intranasal Ketodex combination is non-inferior to intravenous ketamine. All other analyses will test for superiority of intranasal Ketodex. The primary analysis of the
primary outcome will involve logistic regression to model
the dose response relationship for the combinations of
intranasal Ketodex. The optimal dose combination will
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the intranasal sprays using the FPS-R. To detect maladaptive behaviours following discharge, the caregiver will
be surveyed either by telephone or automated email
survey administered by REDCap 24–48 hours following
discharge using the Posthospital Behaviour Questionnaire (PHBQ).29 A schedule of activities is shown in
table 2.
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×
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Informed consent
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Vital signs at triage*
×
Assessment of eligibility ×

Presenting
ED visit
Presenting
Enrolment/
ED visit
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Prescreening evaluation

Schedule of activities

Procedures

Table 2
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Procedures

*Vital signs are normally collected during triage and therefore will always be recorded prior to prescreening for all potential study participant.
†The maximum dose volume administered using the mucosal atomiser device is 0.5 mL per nostril. The administration of each pair of 0.5 mL sprays will be separated by at least 60 s.
‡Video recording will start immediately prior to the closed reduction and will continue until the closed reduction is complete, prior to cast/splint application.
§The PHBQ will be administered either by automatic email from REDCap or by telephone, depending on the participant’s preference.
¶Video scoring using the Paediatric Sedation State Scale will be done by two blinded outcome assessors remote from clinical encounter.
ED, emergency department; PHBQ, posthospital behaviour questionnaire.

Immediately
prior to
cast/splint
application
Immediately
prior to
closed
Closed
reduction
reduction
30–40 min after
intranasal
dexmedetomidine/
saline sprays
First
pair of
intranasal
sprays
Presenting
ED visit
Presenting
Enrolment/
ED visit
baseline
Prescreening evaluation
Continued
Table 2
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be the dose with the maximum posterior expected probability of adequate sedation. We will then consider whether
this optimal dose is non-inferior to intravenous ketamine
by computing the posterior probability of non-inferiority.
If the probability of non-inferiority is above 0.97, then
we will declare that intranasal Ketodex is non-inferior to
intravenous ketamine. This gives a power of 0.92 to detect
that the probability of adequate sedation is equal to 0.9
and a type I error rate of 4.3%. Secondary outcomes will
be assessed using appropriate dose response models for
intranasal Ketodex and posterior updating for intravenous ketamine. An additional analysis will investigate
the interaction between baseline pain and the treatment
effect.
Interim analyses
We will undertake seven interim analyses, at increments
of 50 enrolled participants. Safety outcomes will be
reviewed by the DSMB at each interim analysis. The decision to stop the trial for safety reasons will at the discretion of the DSMB. Due to the ‘unbalanced’ recruitment,
the DSMB will not be blinded to treatment assignment.
We will not undertake comparative effectiveness analyses
at the interim analyses and will not stop for efficacy or
futility.
Missing data
If the percentage of missing data is ≤5%, we will undertake a per protocol analysis. If the percentage of missing
data is >5%, we will use a full Bayesian analysis to jointly
model the missing data model and the outcome model.
Patient and public involvement
The study team’s patient engagement partner (SH) led
a group of four patient partners who informed the trial’s
eligibility criteria, burden of interventions and outcomes.
From their experiences as caregivers of children who
visited a healthcare setting, they reviewed and provided
feedback on the content of the recruitment pitch, letters
of information, consent and assent. Results will not be
directly disseminated to participants but will be provided
on request or through access to the trial’s website (www.
kidscantrials.ca/ipctnetwork).
Data management
Data management services will be provided by the Women
and Children’s Health Research Institute (WCHRI) DCC.
Study data will be entered and managed using REDCap
tools hosted and supported by WCHRI. WCHRI’s REDCap
installation is a electronic, web-based data capture system
validated in accordance with section C.05.012 of the
Health Canada Part C, Division 5 of the Food and Drug
Regulations, ‘Drugs for Clinical Trials Involving Human
Subjects’.
Data will be entered directly into the study database
using a Wi-Fi-enabled encrypted iPad. In the case of a
technical failure, data will be collected on paper and then
transcribed into REDCap by the research nurse or site
coordinator.
Poonai N, et al. BMJ Open 2020;10:e041319. doi:10.1136/bmjopen-2020-041319
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Paediatric Sedation State Scale.

The study participant’s contact information will be
securely stored at each clinical site for internal use during
the study. At the end of the study, all records will continue
to be kept in a secure location for as long a period as
dictated by the reviewing REB, institutional policies or
sponsor requirements. For Health Canada-
regulated
trials, this is 25 years. Individual participants and their
research data will be identified by a unique study identification number.
Monitoring
Monitoring for quality and regulatory compliance will be
performed by the University of Alberta’s Quality Management in Clinical Research (QMCR) office. QMCR is an
independent unit housed within the university’s central
administration that provides arms-
length review of all
University of Alberta sponsored trials, at least three times
per year. Details of clinical site monitoring will be documented in a clinical monitoring plan. This trial will also
be monitored federally by Health Canada (approval
number HC6-24-c230863) and an institutional level by
site-specific clinical research oversight bodies, as per local
requirements.
Safety oversight will be under the direction of the
DSMB, which will function independently of the investigators. This committee will be chaired by Dr Garth
Meckler and is composed of five individuals with expertise in trial methodology, epidemiology, biostatistics and
paediatric emergency medicine. The DSMB will meet at
least semiannually to assess safety and efficacy data and
will operate under the rules of an approved charter/
terms of reference. Interim analyses will be undertaken
at intervals of 50 enrolled participants. The DSMB will, in
collaboration with the trial steering committee, establish
safety stopping rules prior to trial initiation. The DSMB
will be provided with a masked comparison between
treatment groups with respect to the safety endpoints at
the intervals of their choosing. At the DSMB’s request,
Poonai N, et al. BMJ Open 2020;10:e041319. doi:10.1136/bmjopen-2020-041319

they can receive posterior credible intervals or predictive
probabilities. They can further request unmasking. The
decision to stop the trial for safety reasons will be left to
the discretion of the DSMB.
LIMITATIONS
The most important limitation of our work is our inability
to procure a higher concentration of ketamine for intranasal sprays. This will result in a large number of sprays for
heavier participants. Although these individuals may be
more compliant with a greater number of sprays, this may
impact the external generalisability of the work and translation into clinical practice. Some countries (Australia
and the USA) have access to higher concentrations of
intranasal ketamine (100 mg/mL) for clinical use, which
may increase the clinical uptake of our findings.
ETHICS AND DISSEMINATION
Ethics approval was obtained from Clinical Trials Ontario
(London Health Sciences Centre and McMaster Research
Ethics Board #1987). The other participating sites have
yet to receive ethics approval from their institutions. All
protocol amendments will be submitted for approval to
Health Canada before being communicated to each site.
All protocol amendments will be added to the c linicaltrials.gov registration and implemented only after Health
Canada and REB approval. All study participants, or their
caregivers, will be notified if any new findings become
available, which may be in the best medical interest of
the study participant or may impact their willingness to
continue participation in the study.
While long-term risks are not expected, immediate risks
may occur. In terms of safety of intranasal dexmedetomidine, Kim et al35 synthesised the evidence for preoperative
intranasal dexmedetomidine in 11 trials of 1097 children and reported no occurrences of nausea, vomiting,
11
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